The 48 references in paper M. Rasin S., М. Расин С. (2014) “Рецепторы, активирующие пролиферацию пероксисом, в физиологии и патологии легких // Peroxisome proliferator-activated receptors in physiology and pathology of the lung” / spz:neicon:pulmonology:y:2013:i:2:p:95-100

1
Bugge A., Mandrup S.Molecular Mechanisms and GenomeWide Aspects of PPAR Subtype Specific Transactivation. PPAR Research. Volume 2010; Article ID 169506, doi: 10.1155/2010/169506.
(check this in PDF content)
2
Huang J.V., Greyson C.R., Schwartz G.G. PPAR-γas a therapeutic target in cardiovascular disease: Evidence and uncertainty. J. Lipid. Res. 2012; 53 (9): 1738–1754.
(check this in PDF content)
3
Rehan V.K., Torday J.S. PPARγSignaling Mediates the Evolution, Development, Homeostasis, and Repair of the Lung. PPAR Research. Volume 2012; Article ID 289867, doi:10.1155/2012/289867.
(check this in PDF content)
4
Torday J.S., Rehan V.K. Deconvoluting lung evolution using functional / comparative genomics. Am. J. Respir. Cell. Mol. Biol. 2004; 31: 8–12.
(check this in PDF content)
5
Torday J.S, Sun H., Wang L. et al. Leptin mediates the parathyroid hormone-related protein paracrine stimulation of fetal lung maturation. Am. J. Physiol. 2002; 282: L405–L410.
(check this in PDF content)
6
Liu J., Sakurai R., O'Roark E.M. et al.PPARγagonist rosiglitazone prevents perinatal nicotine exposure-induced asthma in rat offspring. Am. J. Physiol. 2011; 300: L710–L717.
(check this in PDF content)
7
Escher P., Wahli W.Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 2000; 448: 121–138.
(check this in PDF content)
8
Расін О.М. Молекулярні механізми протизапальної дії глітазонів та статинів: роль PPAR-γ. Міжнарод. ендокринол. журн. 2007; 6 (12): 71–76.
(check this in PDF content)
9
Кайдашев И.П. NF-κB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза Международ. эндокринол. журн. 2011; 3 (35): 35–40.
(check this in PDF content)
10
Ohshima K., Mogi M., Horiuchi M.Role of peroxisome proliferator-activated receptor-γin vascular inflammation. J. Intern. Vasc. Med. 2012. Internet resource. Volume. 2012.
(check this in PDF content)
11
Hirabara S.M. et al.Molecular Targets Related to Inflammation and Insulin Resistance and Potential Interventions. J. Biomed. Biotechnol. Internet resource. Volume 2012.
(check this in PDF content)
12
Spinelli S.L., O'Brien J.J., Bancos S. et al. The PPAR-platelet connection: modulators of inflammation and potential cardiovascular effects. PPAR Res. 2008; Article ID 328172.
(check this in PDF content)
13
Patel H.J., Belvisi M.G., Bishop+Bailey D. et al. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J. Immunol. 2003; 170: 2663–2669.
(check this in PDF content)
14
Nie M., Corbett L., Knox A.J., Pang L. Differential regulation of chemokine expression by peroxisome proliferatoractivated receptor gamma agonists: Interactions with glucocorticoids and beta 2-agonists. J. Biol. Chem. 2004; 324: 47.
(check this in PDF content)
15
Belvisi M.G., Hele D.J., Birrell M.A. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur. J. Pharmacol. 2006; 533: 101–109.
(check this in PDF content)
16
Lee S.Y., Kang E.J., Hur G.Y. et al.Peroxisome proliferatoractivated receptor-γinhibits cigarette smoke solutioninduced mucin production in human airway epithelial (NCI-H292) cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006; 291: L84–L90.
(check this in PDF content)
17
Honda K., Marquillies P., Capron M., Dombrowicz D. Peroxisome proliferator-activated receptor-γis expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J. Allergy Clin. Immunol. 2004: 113: 882–888.
(check this in PDF content)
18
Hammad H., de Heer H.J., Soullie T. et al.Activation of peroxisome proliferator-activated receptor-γin dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am. J. Pathol. 2004; 164: 263–271.
(check this in PDF content)
19
Lee K.S., Park S.J., Kim S.R. et al. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor γin a murine model of toluene diisocyanate-induced asthma. J. Immunol. 2006; 177: 5248–5257.
(check this in PDF content)
20
Milam J.E., Keshamouni V.G., Phan S.H. et al.PPARgamma agonists inhibit pro-fibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008; 294: L891–L901.
(check this in PDF content)
21
Hogan C.M., Thatcher T.H., Sapinoro R.E. et al. Electrophilic PPARγligands attenuate IL-1βand silica-induced inflammatory mediator production in human lung fibroblasts via a PPARγ-independent mechanism. PPAR Res. 2011; Article ID 318134.
(check this in PDF content)
22
Michalik L., Desvergne B., Wahli W.Peroxisome-proliferator-activated receptors and cancers: complex stories. Nature Rev. Cancer 2004; 4 (1): 61–70.
(check this in PDF content)
23
Ward J.E., Fernandes D.J., Taylor C.C. et al.The PPARγligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation. Pulm. Pharmacol. Ther. 2006; 19 (1): 39–46.
(check this in PDF content)
24
Stegenga M.E., Florquin S., de Vos A.F., van der Poll T. The thiazolidinedione ciglitazone reduces bacterial outgrowth and early inflammation during streptococcus pneumoniae pneumonia in mice. Crit. Care Med. 2009; 37 (2): 614–618.
(check this in PDF content)
25
Belvisi J.A.M., Maria G.Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br. J. Pharmacol. 2009; 158 (4): 994–1003.
(check this in PDF content)
26
Becker J., Delayre+Orthez C., Frossard N., Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam. Clin. Pharmacol. 2006; 20: 429–447.
(check this in PDF content)
27
Cuzzocrea S., Bruscoli S., Mazzon E. et al.PPAR-alpha contributes to the anti-inflammatory activity of glucocorticoids. Mol. Pharmacol. 2007; 73: 323–337.
(check this in PDF content)
28
Reddy R.C., Rehan V.K., Roman J., Sime P.J. PPARs: Regulators and translational targets in the lung. PPAR Res. 2012; Article ID 342924. doi: 10.1155/2012/342924.
(check this in PDF content)
29
Чучалин А.Г. Идиопатический легочный фиброз. Тер. арх. 2000; 3: 5– 12.
(check this in PDF content)
30
Burgess H.A., Daugherty L.E., Thatcher T.H. et al. PPARgamma agonists inhibit TGF-induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 288: 1146–1153.
(check this in PDF content)
31
Delayre+Orthez C., Becker J., Auwerx J. et al. PPAR-alpha decreases airway inflammation associated with asthma in the mouse. Fundam. Clin. Pharmacol. 2004; 18: 220.
(check this in PDF content)
32
Lakatos H.F., Thatcher T.H., Kottmann R.M. et al. The role of PPARs in lung fibrosis. PPAR Res. 2007; Article ID 71323.
(check this in PDF content)
33
Чучалин А.Г.Новые перспективы лечения тяжелой бронхиальной астмы: в фокусе внимания атопия. Здоров'я України 2008; 9 (1): 32–33.
(check this in PDF content)
34
Kohansal R., Martinez+Camblor P., AgustíA. et al.The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring Cohort. Am. J. Respir. Crit. Care Med. 2009; 180 (1): 3–10.
(check this in PDF content)
35
Амелина Е.Л., Черняк А.В., Чучалин А.Г. Муковисцидоз взрослых: особенности ведения. Пульмонология 2006; прил. по муковисцидозу: 30–35.
(check this in PDF content)
36
Lee S.Y., Kang E.J., Hur G.Y. et al.Peroxisome proliferatoractivated receptor-γinhibits cigarette smoke solutioninduced mucin production in human airway epithelial (NCI-H292) cells. Am. J. Physiol. 2006; 291 (1): L84–L90.
(check this in PDF content)
37
Liu D.S., Liu W.J., Chen L. et al. Rosiglitazone, a peroxisome proliferator-activated receptor-γagonist, attenuates acrolein-induced airway mucus hypersecretion in rats. Toxicology 2009; 260 (1–3): 112–119.
(check this in PDF content)
38
Yongchun S., Wen F. PPARγas a potential target to treat airway mucus hypersecretion in chronic airwayю inflammatory diseases. PPAR Res. 2012; Article ID 256874. doi: 10.1155/2012/256874.
(check this in PDF content)
39
Lee J.+M., Kim S.S., Cho Y.+S. The role of PPARγin helicobacter pylori infection and gastric carcinogenesis. PPAR Res. 2012; Article ID 687570.
(check this in PDF content)
40
Han S., Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol. Cancer Ther. 2006; 5 (2): 430–437.
(check this in PDF content)
41
Kulkarni A.A., Woeller C.F., Thatcher T.H. et al.Emerging PPARγ-Independent Role of PPARγLigands in Lung Diseases. PPAR Res. 2012; Article ID 705352.
(check this in PDF content)
42
Keshamouni V.G., Reddy R.C., Arenberg D.A. et al. Peroxisome proliferator-activated receptor-γactivation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004; 23 (1): 100–108.
(check this in PDF content)
43
Colin C., Salamone S., Grillier+Vuissoz I. et al.New troglitazone derivatives devoid of PPARγagonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Res. Treat. 2010; 124 (1): 101–110.
(check this in PDF content)
44
Fulzele S.V., Chatterjee A., Shaik M.S. et al.15-Deoxyδ12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anti-Cancer Drug 2007; 18 (1): 65–78.
(check this in PDF content)
45
Liby K., Voong N., Williams C.R. et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin. Cancer Res. 2006; 12 (14): 4288–4293.
(check this in PDF content)
46
Wright H.M., Clish C.B., Mikami T. et al.A synthetic antagonist for the peroxisome proliferator-activated receptor-γ inhibits adipocyte differentiation. J. Biol. Chem. 2000; 275 (3); 1873–1877.
(check this in PDF content)
47
Girnun G.D., Chen L., Silvaggi J. et al.Regression of drugresistant lung cancer by the combination of rosiglitazone and carboplatin. Clin. Cancer Res. 2008; 14 (20): 6478–6486.
(check this in PDF content)
48
Pioglitazone hydrochloride in treating patients with stage I, stage II, or stage III non-small cell lung cancer. Clinical Trials. Gov Identifier: NCT01342770. Информация об авторе Расин Михаил Сахнович– проф. кафедры внутренних болезней No 3
(check this in PDF content)